Colon Neoadjuvant FOLFOXIRI Study
Objective tumour response rate to FOLFOXIRI to pre-operative therapy.
Rectal Cancer
DRUG: neoadjuvant FOLFOXIRI|DRUG: Capecitabine
Objective tumour response rate, 2 years
Tumour regression grade, 2 years|pathologic complete response, 2 years|Rate of circumferential resection margin (CRM) clearance, 2 years|Rate of tumour downstaging, 2 years|Number of Participants with Adverse Events, 2 years|Overall survival, 5 years|disease-free survival, relapse-free survival, 5 years|Time to local (and distant) recurrence, 5 years|Number of patients with 30-day post-operative mortality, 1 month|Compliance to study treatment, 2 years|Number of response to neoadjuvant therapy, 2 years
Objective tumour response rate to FOLFOXIRI to pre-operative therapy.